ARES Ares Management

Q3 2025 10-Q
Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR

Ares Management (ARES) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

  • Revenue $2.40B, up 1% YoY (+$12M); nine months revenue $7.08B, up 2% YoY (+$141M) with 3% operational growth
  • Operating margin U.S. 83.2% vs 80.8% YoY Q3; International 68.6% vs 68.6% flat Q3; Nine months U.S. 83.7% vs 81.5%, Intl 69.8% vs 68.1%
+3 more insights

Risk Factors

  • New risk: Impact of dynamic and unpredictable new tariffs and trade restrictions on costs and supply chains triggered by recent foreign trade policy changes
  • Most updated risk: Increased supply chain disruptions and labor/material cost volatility due to evolving tariffs and geopolitical tensions affecting third-party suppliers
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$2.4B

+0.5% YoY -2.4% QoQ

Net Income

$721M

+5.7% YoY +0.4% QoQ

Net Margin

30.0%

+148bp YoY +85bp QoQ

Source: XBRL data from Ares Management Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Ares Management Quarterly Reports

Get deeper insights on Ares Management

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.